PRNAF (Alterity Therapeutics) Research & Development: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRNAF Alterity Therapeutics Ltd PRNAF
29 GF Score
Price $0.35
View Full Analysis

What is Alterity Therapeutics Research & Development?

Alterity Therapeutics PRNAF 29 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates PRNAF with a GF Score™ of 29/100.

Research & Development is the aggregate amount of research and development expenses during the year. Alterity Therapeutics's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Alterity Therapeutics  (OTCPK:PRNAF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alterity Therapeutics Research & Development Related Terms

Alterity Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Research & Development Chart

Alterity Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.36 8.86 12.38 9.38 0.00

Alterity Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PRNAF
29GF Score
Alterity Therapeutics Ltd PRNAF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Alterity Therapeutics (PRNAF) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Research & Development too high?
Alterity Therapeutics' current Research & Development is $0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Research & Development compare to VRTX and REGN?
Alterity Therapeutics' Research & Development of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (PRNAF) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Alterity Therapeutics' overall GF Score™ is 29/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alterity Therapeutics (PRNAF), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
29GF Score

Get the complete analysis for PRNAF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price